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Acute coronary syndrome (ACS) is a costly health care issue worldwide.
1 Numerous well-conducted clinical trials have demonstrated that early intervention is associated with the greatest long-term survival, better myocardial preservation, and improved quality of life. Consequently, inpatient cardiovascular procedures in the United States have increased over 4-fold since 1979. 1 Notably, the use of antiplatelet therapies has increased well beyond this number and has affected the management of the one-quarter million patients who undergo cardiac surgery each year. The use of antithrombotic agents carries a risk of minor and major bleeding, notably when patients undergo coronary artery bypass grafting (CABG) in the early phase of ACS, the time at which antithrombotic use is greatest and most effective. Concerns over excess bleeding in patients undergoing CABG may lead to withholding antiplatelet agents, perhaps sacrificing early benefit for some patients. The use of blood products, notably platelet transfusions, to treat bleeding has short-and longterm risks that have not yet been balanced against the risks of decreased myocardial survival associated with nonuse of antiplatelet therapy. A better understanding of the risks and benefits associated with early antiplatelet therapy is necessary to improve the outcomes of all patients with ACS, including those who undergo CABG.
VALUE OF EARLY INTERVENTION IN ACS
Numerous clinical trials conducted over 3 decades have rigorously evaluated management strategies for ACS. These studies have shown that early intervention combined with appropriate antiplatelet agent use results in significantly improved outcomes. The findings of these trials have been used to generate the well-stated and widely used American College of Cardiology/American Heart Association (ACC/ AHA) clinical guidelines for ACS management. 2, 3 Results of trials such as FRISC-II (Fast Revascularization during Instability in Coronary artery disease-II), 4 ISAR-COOL (Intracoronary Stenting with Antithrombotic Regimen COOLing off), 5 and ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) 6 exemplify the value of antiplatelet drugs in early ACS treatment. However, the value of early coronary intervention accompanied by profound inhibition of platelet aggregation and thrombus formation incurs an increased risk of bleeding, which has its own attendant morbidity and mortality. Despite the additional risk of bleeding, the use of appropriate pharmacotherapy in patients with ACS is paramount. Recognition of both the benefit of early interventional therapy in patients with ACS with the simultaneous finding of benefit for antiplatelet therapies has led to critical issues in developing strategies that best combine these tactics while minimizing potential risk. Central to this discussion is the following paradox: cardiologists want intensive antiplatelet therapy, frequently with multiple agents, to avoid thrombosis whereas surgeons want to minimize antiplatelet therapy to avoid bleeding. Thus, there is tension in balancing the risks of bleeding and transfusion against improved long-term outcomes in a frequently used treatment pattern for patients with ACS consisting of early intervention and later CABG. Although significant evidence exists to address this concern, it is unclear whether the perception of bleeding risk with antiplatelet agents is aligned with actual evidence for the real risk-versus-benefit equation.
PLATELET INHIBITION AND THE RISK OF BLEEDING
A wealth of clinical trial data provides evidence for the benefit of antiplatelet therapy in preventing recurrent ischemia after ACS. 7, 8 This is a critical consideration in secondary prevention, particularly in the perioperative period when platelet activity is high and associated with significant risk for a second, potentially fatal ischemic event. It is therefore imperative that a timely antiplatelet strategy be implemented with due consideration for the potential and real risk of abruptly stopping such beneficial therapy because of bleeding concerns in patients undergoing CABG.
Intrinsic to any strategy for inhibiting platelet function is the increased risk for bleeding. Bleeding is usually classified according to clinical or laboratory criteria as major (life-threatening, severe) or minor. 9 However, bleeding definitions have not been uniformly applied, leading to as much as a 3-fold difference in the reported incidence of major bleeding ( Figure 1 ). 10 Points of discrepancy between criteria for major bleeding include a decrease in hemoglobin (from ! 3 g/dL to ! 5 g/dL), a requirement for transfusion (! 1 unit or ! 2 units), or a requirement for an overt source of bleeding.
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A growing body of evidence shows that, regardless of the classification system applied, bleeding is an independent predictor of adverse clinical outcomes. TIMI (Thrombolysis In Myocardial Infarction) major bleeding, GUSTO (Global Utilization of Strategies To Open occluded arteries) moderate or severe bleeding, and a drop in hemoglobin have all been associated with early mortality and/or other adverse cardiovascular events within 30 days 10 ; whether such bleeding is also associated with mortality at 6 months or 1 year is currently unclear. Thus, the prevalence and risk for bleeding in patients with ACS with or without intervention, remains a significant concern requiring careful consideration to balance the risk of bleeding with the benefit of antiplatelet therapies.
ANTIPLATELET THERAPIES AND INTERVENTION
Based on the importance of antiplatelet therapy in treating ACS, evidence-based guidelines for their use have been prepared. 2, 3 Because aspirin and clopidogrel are the only antiplatelet therapies currently recommended at a class I level for both immediate and long-term use in patients with ACS they will be the main focus of the remaining discussion.
Historically, the benefits of early aspirin use in the treatment of patients with ACS have been well established.
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For patients undergoing CABG preoperative aspirin use has been associated with improved graft patency and reduces the risk of perioperative myocardial infarction (MI), in-hospital mortality, and other adverse postoperative outcomes (Table E1) .
Older aspirin studies sparked debate around aspirin use in CABG inasmuch as they showed that preoperative aspirin use was associated with increased blood loss, greater transfusion rates, and higher re-exploration rates (Table E2 ). However, numerous subsequent studies have described no significant increase in bleeding complications in patients undergoing CABG receiving aspirin in the 7 days before surgery (Tables E2 and E3 ). Thus, aspirin is not a significant risk factor for bleeding or transfusion.
The efficacy of dual antiplatelet therapy with aspirin and clopidogrel has been compared with aspirin monotherapy in patients with ACS and those undergoing percutaneous coronary intervention (PCI). The results of these large, prospective, randomized trials show that adding clopidogrel to aspirin consistently reduces the risk of adverse events, in most cases, without significantly increasing the risk of bleeding (Table E4) . Overall, there is a clear, consistent benefit associated with clopidogrel pretreatment before PCI, and the reduction in cardiovascular events before PCI suggests that clopidogrel pretreatment should be initiated as soon as possible. Although the risk of bleeding may be greater with dual antiplatelet therapy, the excess risk is not enough to outweigh the benefits.
Data also suggest that aspirin and clopidogrel improve clinical outcomes without being associated with increased bleeding after CABG. 12, 13 Among the 1013 patients in the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) study who received CABG during their index hospitalization, dual antiplatelet therapy reduced the relative risk of cardiovascular death, MI, and stroke by 19% compared with patients who received aspirin alone (relative risk, 0.81; 95% confidence interval [CI], 0.59-1.12); the bulk of this benefit was due to an 18% reduction in the relative risk of events occurring before surgery (relative risk, 0.82; 95% CI, 0.58-1.16). 12 Among the 136 CLARITY (Clopidogrel as Adjunctive ReperfusIon TherapY) patients who underwent CABG, dual therapy with aspirin and clopidogrel reduced the risk of cardiovascular death, MI, and recurrent ischemia by 34% compared with those who received aspirin (odds ratio, 0.66; 95% CI, 0.27-1.63), a benefit due entirely to a reduction in MI and recurrent ischemia before surgery (odds ratio, 0.46; 95% CI, 0.16-1.36). 13 Results of other studies disagree with those of CURE and CLARITY inasmuch as they show an increased risk of procedural bleeding, re-exploration, blood product usage, and chest drain blood loss in patients undergoing CABG receiving clopidogrel and aspirin, particularly within 5 to 7 days of the operation (Tables E2 and E3 ).
THE CABG CONUNDRUM
Only 7% to 12% of patients with non-ST-elevation MI and 4% of patients with ST-elevation MI undergo CABG. 14, 15 Further, fewer than 1% of all CABG operations are done on an emergency basis (immediately after failed PCI). 16 Given that CABG is performed in only a minority of patients, is effective antiplatelet treatment being withheld from the majority for the benefit of the minority?
The preponderance of evidence indicates that clopidogrel exposure within 5 to 7 days of CABG is associated with excess bleeding (Tables E2 and E3 ); thus, current guidelines recommend a clopidogrel washout period of 5 to 7 days before planned CABG. 2, 3 However, it is not clear how clopidogrel-associated excess bleeding has affected CABG clinical practice. Although transfusion rates are driven by institutional and practitioner preferences, they do provide some estimation of bleeding after CABG surgery. Thus, one way to loosely assess the effect of escalated platelet inhibition on CABG clinical practice is to examine the transfusion requirements reported for different antiplatelet regimens (Tables E2 and E3 ). Caveats to such comparisons include the potential masking effect of advancing surgical techniques, 17 the varying transfusion thresholds among hospitals, 18 the nonhomogeneous use of antiplatelet regimens perioperatively, 19 and physician biases toward prophylactic, and perhaps unnecessary, transfusion of plasma and platelets in clopidogrel-treated patients. 18 Given these caveats, observational data suggest that transfusion rates for patients undergoing CABG have remained relatively unchanged in the dual antiplatelet therapy era. In the early days of CABG, almost all patients received a transfusion. 20 With the advent of hemodilution and concerns over the quality of the blood supply, efforts were made to reduce blood transfusions throughout the 1980s and beyond. Examination of the data shows that although the amount of blood loss has increased anywhere from 30% to 100% along with escalated platelet inhibition, the percentage of patients receiving transfusions (between 20% and 60% depending on the study) and the amount of blood transfused per patient (mean of 2 to 3 units) has remained approximately the same (Tables E2 and E3 ). For this issue to be addressed more effectively, however, there is a need for prospective collection of post-CABG bleeding and transfusion rates in all clinical trials of antiplatelet agents.
The percentage of patients who have an adverse myocardial event while waiting for clopidogrel washout is not known. Although data from some studies support the CURE and CLARITY findings that fewer clopidogrelexposed patients have adverse outcomes, data from other studies suggest the opposite. 19, 21 It is possible to extrapolate data from PCI-CURE, in which the time to PCI was 6 days and the incidence of an MI while waiting for intervention was 5.1% in the placebo group and 3.6% in the clopidogrel group (P ¼ .04; number needed to treat ¼ 66 to prevent an MI before PCI). Such an extrapolation suggests that the reduction in blood loss, risk of re-exploration, and blood product usage that accompanies cessation of clopidogrel for 5 to 7 days before CABG comes at the expense of approximately a 1% increase in the risk of MI while waiting for surgery. 22 This rate may be highest in the period immediately after the first ACS event and may decline in the weeks or months that precede elective CABG.
Whether a reduced risk of bleeding is worth an increased risk of additional ischemic events remains an issue for continued debate. Adding to this debate are important considerations regarding the direct and indirect economic and social costs of hospitalization on patients and their families resulting from potentially unnecessary delays in CABG. In one study comparing resource use in a CABG patient cohort, the costs for those who underwent nonelective CABG were 33% higher than the costs for those who underwent elective CABG, a difference due almost entirely to costs incurred during a longer preoperative length of stay. 23 Prolonged lengths of stay also expose patients, particularly those who are elderly, to the development of comorbid conditions related to long hospital stays, including decubitus ulcers (bed sores) and nosocomial infections. One way to limit the overall impact of a clopidogrel washout period may be to discharge patients to home, as results of a retrospective analysis of 125 patients who received CABG within 3 to 5 days of clopidogrel cessation showed that those discharged to home had similar intraoperative and postoperative outcomes as those who remained hospitalized. 24 Overall, additional information on the risks of clopidogrel washout before CABG is needed.
FUTURE DIRECTIONS
The absence of reliable, easy, and quick platelet function testing for patients receiving a wide variety of antiplatelet drugs is a serious problem. There are several commercially available platelet function tests, but the overall utility of platelet function testing is limited by poor reproducibility and comparability among tests. Variability in response to antiplatelet agents, perhaps especially marked for the prodrugs, makes estimation of dosing and timing of antiplatelet administration very difficult. Furthermore, if physicians were able to more precisely determine which patients were at the greatest risk of bleeding, as well as the time at which antiplatelet-exposed patients could be safely operated on, appropriate upstream initiation of therapy might increase. For such a scenario to come to fruition, a single reproducible and inexpensive test to measure platelet inhibition is necessary.
CONCLUSION
Antiplatelet therapy is a mainstay of care for patients with ACS, and the majority of these patients benefit from its early use, as evidenced by a reduced risk of cardiovascular events while awaiting interventional revascularization. The vast majority of patients with ACS receive PCI as opposed to CABG; therefore, waiting to confirm coronary anatomy before initiating antiplatelet therapy would be to the detriment of 90% to 95% of patients if one considers that only 5% to 12% of patients with ACS undergo CABG. 14, 15 Although antiplatelet therapy is associated with clinical benefit in patients undergoing CABG, it also increases the risk of bleeding in some, but not all, patients. Although prolonged cessation of clopidogrel in patients undergoing CABG before the procedure is associated with a reduction in perioperative blood loss and blood product usage and a reduced risk of re-exploration, these benefits come at the expense of a 1% increase in the risk of MI while awaiting surgery. 22 Inasmuch as previous bleeding concerns associated with aspirin use before CABG have been overcome with increased clinical experience, the risk of bleeding with dual antiplatelet therapy may be reduced with increased operator experience and adjunctive therapeutic agents such as the lysine analogs to reduce surgical bleeding. Overall, strategies aimed at reducing the risk of bleeding should not compromise the clinical benefit of antiplatelet therapy. In the future, platelet function testing may increase the use of appropriate upstream antiplatelet therapy by helping surgeons determine when the risk of bleeding is lessened in antiplatelet-exposed patients. If no percentage is reported, it was not available in the original manuscript. For details of the individual studies (study design, number of subjects, and antiplatelet regimens studied), see Table E4 . APT, Antiplatelet; ASA, aspirin; CABG, coronary artery bypass grafting; CLO, clopidogrel; d, day; DP, dipyridamole; FFP, fresh frozen plasma; NR, not reported; sulf, sulfinpyrazone; tid, three times daily. All patients received aspirin in addition to either clopidogrel, prasugrel, or placebo; b CURE criteria for major bleeding (substantially disabling bleeding, intraocular bleeding leading to vision loss, bleeding necessitating transfusion of ! 2 units of blood); c P value not provided; 95% confidence interval (0.71-1.11); d TIMI criteria for major bleeding (intracranial bleeding or bleeding associated with a hemoglobin drop ! 5 g/dL); e COMMIT criteria for major bleeding (fatal bleeding, cerebral bleeding, any bleeding that required transfusion).
